Statins represent a class of drugs that are capable of regulating the biosynthesis of cholesterol by inhibiting the enzyme that reduces 3-hydroxy-3-methylglutaric acid to mevalonic acid, namely, the HMG-CoA reductase inhibitors. Since the introduction of pravastatin by Sankyo and lovastatin by Merck to the pharmaceutical market, this class of drugs has been in eminent demand. Due to the importance of these drugs, various synthetic strategies aimed at the construction of statins have been reported.Many of these studies have focused on the introduction of the statin side chain.1 During the course of our efforts to develop a facile synthesis of HMG-CoA reductase inhibitors, a three-step linear synthesis of fluvastatin 5 has been identified and successfully implemented. Most of the statins, such as atorvastatin calcium hydrate, simvastatin, and pravastatin sodium, are administered in the optically pure form. However, to our knowledge, fluvastatin has been approved as a racemic form. Actually, Novartis’ group reported manufacturing process for fluvastatin in racemic form.2 As for chiral version, Prasad and his